Floatz logo

plx038

Extra-Pulmonary Small Cell Carcinomas

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Extra-Pulmonary Small Cell Carcinomas cohort.

Asset / SponsorPhaseRating
Hycamtin
National Cancer Institute (NCI)
Phase 2BB
Vinorelbine
EpicentRx, Inc.
Phase 2BB
Lurbinectedin
SystImmune Inc.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
EpicentRx, Inc.
Phase 2BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB

View all 31 →

Same molecule, other indications

plx038 is also rated in:

ovarian carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
fallopian tube carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
primary peritoneal carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →